Nordic Nanovector Presentations at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting
Oslo, Norway, 11 June 2019 Nordic Nanovector ASA (OSE: NANO) announces that the company and its collaborators will present data and analyses from its preclinical studies with Betalutin® (177Lu-lilotomab satetraxetan) and with 212Pb-NNV003, a next-generation targeted alpha therapy comprising Nordic Nanovector’s chimeric anti-CD37 antibody (NNV003) coupled with the alpha-particle-generator lead-212 (212Pb), at the Society of Nuclear Medicine & Molecular Imaging (SNMMI) 2019 Annual Meeting, to be held in Anaheim, CA, USA on 22-24 June. Details of the presentations are: Combination of